<DOC>
	<DOCNO>NCT02521714</DOCNO>
	<brief_summary>This study evaluate amount drug reach circulation subject take test ( liquid ) formulation compare reference ( capsule ) formulation . The study also examine effect high fat meal level drug blood .</brief_summary>
	<brief_title>Study Evaluatethe Bioavailability Food Effect Lenalidomide Oral Suspension</brief_title>
	<detailed_description>This phase 1 , open-label , randomize , three-period , two-way crossover study healthy subject . The study consist screen phase , baseline phase , three treatment period , follow-up phone call . Each period two day duration ( Day 1 Day 2 ) dose sample collection . There minimum four day washout dos . Within 21 day ( Day -21 ) less two day ( Day -2 ) prior start Period 1 , subject undergo routine screening procedure include physical examination ( PE ) , 12-lead electrocardiogram ( ECG ) , vital sign , clinical laboratory safety test ( serum chemistry , hematology , urinalysis ) , serology screen , drug/alcohol screen . Eligible subject admit study center Day -1 Period 1 baseline assessment . During period , subject receive single 25 mg oral dose lenalidomide Day 1 accord assign treatment sequence . Serial blood sample determination lenalidomide concentration plasma perform 24 hour post dose , safety evaluate . Subjects domicile study center Day 1 Period 1 Day 2 Period 3 , include 4 day washout dose IP . All subject discharge study center Day 2 Period 3 follow completion require study procedure . A follow-up phone call occur approximately four day ( ±2 day ) discharge study center . The study conduct compliance International Conference Harmonisation ( ICH ) Good Clinical Practices ( GCPs ) .</detailed_description>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Subjects must satisfy follow criterion enrol study : 1 . Males female ( nonchildbearing potential ) race 18 year age 65 year age time sign informed consent document . 2 . Subject must understand voluntarily sign informed consent prior studyrelated assessments/procedures conduct . 3 . Subject willing able adhere study visit schedule protocol requirement . 4 . Must able communicate investigator , understand comply requirement study , agree adhere restriction examination schedule 5 . Male subject Must agree practice complete abstinence ( True abstinence acceptable line prefer usual lifestyle subject . Periodic abstinence [ eg , calendar , ovulation , symptothermal , post ovulation method ] withdrawal acceptable method contraception . ) agree use condom sexual contact pregnant female female childbearing potential ( FCBP ) take lenalidomide , dose interruption , least 28 day last dose lenalidomide , even undergone successful vasectomy . Must donate semen sperm receive lenalidomide , dose interruption , least 28 day last dose lenalidomide . 6 . Counseling pregnancy precaution potential risk fetal exposure must conduct described Lenalidomide Pregnancy Prevention Plan . 7 . Must body mass index ( BMI ) 18 33 kg/m2 ( inclusive ) . 8 . Clinical laboratory test must within normal limit consider clinically significant investigator . 9 . Must confirmation normal renal function . 10 . Must afebrile supine systolic blood pressure : 90 140 mmHg , supine diastolic blood pressure : 50 90 mmHg , pulse rate : 40 110 beat per minute screen visit . Vital sign may repeat three time determine eligibility . 11 . Must normal clinically acceptable 12lead electrocardiogram , QTcF value ≤ 450 msec male subject ≤ 470 msec female subject . The presence follow exclude subject enrollment : 1 . Any significant medical condition ( e.g. , renal insufficiency ) , laboratory abnormality , psychiatric illness would prevent subject participate study . 2 . Any condition include presence laboratory abnormality , place subject unacceptable risk he/she participate study . 3 . Any condition confound ability interpret data study . 4 . Used prescribed systemic topical medication within 30 day first dose administration , unless Sponsor agreement obtain . 5 . Used nonprescribed systemic topical medication ( include vitamin/mineral supplement , herbal medicine ) within 14 day first dose administration , unless Sponsor agreement obtain . 6 . Has surgical medical condition ( exclude appendectomy ) possibly affect drug absorption , distribution , metabolism excretion , eg , bariatric procedure , cholecystectomy . 7 . Donated blood plasma within 8 week first dose administration blood bank blood donation center . 8 . History drug abuse ( define current version Diagnostic Statistical Manual within 2 year first dose administration , positive drug screen test reflect consumption illicit drug . 9 . History alcohol abuse ( define current version DSM ) within 2 year first dose administration , positive alcohol screen . 10 . Known serum hepatitis know carrier hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCVAb ) , positive result test HIV antibodies Screening . 11 . Exposed investigational drug ( new chemical entity ) within 30 day precede first dose administration , 5 halflives investigational drug , know ( whichever longer ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Revlimid</keyword>
	<keyword>lenalidomide</keyword>
	<keyword>bioavailability</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>food effect</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>